HK Stock Market Move | PEGBIO CO-B(02565) rose more than 7% to hit a new high, and the PB-119 listing registration application has been accepted, with domestic commercialization about to be realized.

PEGBIO CO-B (02565) rose by more than 7%, reaching a high of 38.66 Hong Kong dollars, setting a new record high in the market. As of the time of publication, it has increased by 5.84%, closing at 38.04 Hong Kong dollars, with a trading volume of 18.8928 million Hong Kong dollars. On the news front, Peg BioPharmaceutical recently released its interim performance report. The group generated other net income of RMB 178,000, with research and development expenses of RMB 26.294 million, resulting in a loss of 0.25 yuan per share. The company stated that due to the acceptance of the NDA for PB-119 by the National Medical Products Administration, it expects to commercialize PB-119 in China in the near future. After the listing, the company anticipates incurring related costs as a listed company. Due to the development status of the candidate drugs, potential collaboration with partners, regulatory approval timelines, and commercialization of candidate drugs, the expected financial performance will fluctuate over different periods. Furthermore, the announcement indicated that Peg BioPharmaceutical has successfully built a pipeline matrix covering six investigational drugs in the field of chronic diseases. The company's core strategy focuses on the treatment of metabolic diseases and their complications. Through continuous innovation, internal assessments show that multiple candidate drugs have dual value potential of "First in class" (FIC) and "Best in class" (BIC), laying a solid foundation for future market competitiveness.